iSpecimen Inc. (ISPC): Cash & Equivalents
$6.88M
As of 2025-12-31
$4.41M
As of 2026-06-30
-23.4%
3-year compound annual growth
+58.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.88M | +266.3% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $1.88M | -19.9% | 2026-04-01, Balance as of period end |
| 2023-12-31 | $2.34M | -84.7% | 2025-04-14, Balance as of period end |
| 2022-12-31 | $15.31M | -44.8% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $27.74M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $695.9K | n/a | 2022-03-22, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.88M | +266.3% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $585.0K | +240.1% |
| Absci Corp (ABSI) | 2025-12-31 | $20.02M | -51.4% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $6.45M | +483.5% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $207.5K | +203.9% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $25.52M | -7.5% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $20.07M | -28.0% |
| NRC Health (NRC) | 2025-12-31 | $4.14M | -2.2% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $497.05M | -25.8% |
Compare ISPC, ONMD, ABSI, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗